Background:Vitamin D deficiency may play a key role in the development of impaired glucose tolerance, type 2 diabetes mellitus (T2DM), and metabolic syndrome. Several studies have shown that Vitamin D has an antioxidant property. We aimed to investigate 25-hydroxy Vitamin D (25[OH]D) levels in patients with T2DM and in nondiabetic healthy controls and to ascertain the impact of 25(OH)D levels on glycemic control and oxidative stress in T2DM patients.Materials and Methods:Thirty male patients with T2DM and twenty age- and socioeconomic status-matched male healthy controls were included in the study. Fasting and postprandial blood sugar and glycated hemoglobin (HbA1c) were measured. Enzyme activity of superoxide dismutase (SOD) and glutathione peroxidase (GPx) was determined by spectrophotometric assay, and serum levels of 25(OH)D were measured using radioimmunoassay.Results:Serum Vitamin D levels were significantly lower in patients with T2DM than healthy controls (P = 0.015). There was a significantly lower GPx activity in patients with T2DM than controls (P = 0.048), but the difference in SOD activity did not reach statistical significance. There was a significant negative correlation between serum Vitamin D levels and HbA1c (P = 0.016), but no statistical correlation was shown between serum Vitamin D levels and GPx and SOD.Conclusion:We conclude that low level of Vitamin D might play a significant role in T2DM pathogenesis. Hence, Vitamin D supplementation may improve glycemic control and oxidative stress in T2DM.
SummaryBackground Colorectal cancer (CRC) is one of the most common cancers worldwide. The tumor microenvironment is very important for determining cancer cell growth and spreading. Chemerin, a newly identified adipokine secreted by adipose tissue, is known to be associated with obesity, metabolic syndrome, and insulin resistance. The present study was carried out to investigate the association between serum levels of chemerin and colorectal cancer.MethodsThirty-two patients with colorectal cancer aged 57.6±6.5 years, and twenty age, sex and BMI matched healthy controls were included in the study. Serum che me rin levels were determined using enzyme linked immuno sorbent assay. C-reactive protein (CRP) levels were determined using a turbidimetric immunoassay. Carcino embryonic antigen (CEA) and carbohydrate antigen (CA 19-9) were measured by radioimmunoassay.ResultsChemerin levels were found to be significantly higher in patients relative to the controls (P<0.001) and gradually increased with the TNM tumor stage progression. The mean CRP, CEA and CA 19-9 levels were also significantly higher in patients (P<0.001). There was a significant correlation between the serum levels of chemerin and the other measured parameters in CRC patients. The area under receiver operating characteristic curve (ROC) for serum chemerin was 1 at a cut-off value ≥ 161.5 with 100% sensitivity and 100% specificity.ConclusionsConclusions: The observed results suggest that chemerin may have a potential role in the pathogenesis and progression of colorectal malignancy and may be a good biomarker of colorectal cancer and stage progression.
Background: CXC chemokine ligand 16 (CXCL16) is an inflammatory chemokine that mediates renal infiltration of macrophages and activated T cells. Aim: To investigate serum levels of CXCL16 in patients undergoing hemodialysis and their correlation with other inflammatory markers such as C-reactive protein (CRP) and intact parathyroid hormone (iPTH). Methods: The study included 40 hemodialysis patients (22 males) and 40 age and gender-matched controls (24 males). Fasting blood sugar (FBS), urea, creatinine, calcium and inorganic phosphorous were assayed in participants using routine methods, glycosylated hemoglobin (HbA1c) by quantitative chromatographic spectrophoto metry, iPTH by chemiluminescent microparticle immuno assay, CRP by nephelometry and CXCL16 by ELISA technique. Results: Serum CXCL16, CRP, PTH, FBS, HbA1c, phosphorus, urea, and creatinine levels were significantly higher in hemodialysis patients compared to controls (p<0.00001). No statistically significant differences were observed between patients and controls for calcium. Serum CXCL16 levels correlated positively with CRP (r=0.956, p<0.00001) and iPTH (r=-0.403, p<0.001). Hemodialysis patients (diabetics or hypertensives) had significantly higher CXCL16 levels compared to non-diabetics or non-hypertensives. Kratak sadr`ajUvod: CXC hemokin ligand 16 (CXCL16) je infalamatorni hemokin koji posreduje u bubre`noj infiltraciji makrofaga i aktivira T }elije. Cilj: Svrha ovog rada je bila da se ispitaju nivoi serumskog CXCL16 u pacijenata koji su bili na hemodijalizi i njihova korelacija sa drugim inflamatornim markerima kao {to su Creaktivni protein (CRP) i intaktni paratireoidni hormon (iPTH). Metode: Izu~avanje je obuhvatilo 40 pacijenata na hemodijalizi (22 mu{karca) i kontrolnu grupu starosti 40 godina (24 mu{karca). Glukoza na ta{te (FBS), ureja, kreatinin, kalcijum i neorganski fosfat su kod ispitanika odre|ivani rutinskim metodama, glikozilirani hemoglobin (HbA1c) primenom kvantitativne hromatografske spektrometrije, iPTH hemiluminiscentnim imunoodre|ivanjem, CRP nefelometrijski i CXCL16 primenom ELISA tehnike. Rezultati: Nivoi CXCL16, CRP, iPTH, FBS, ureje i kreatinina su bili zna~ajno vi{i kod pacijenata na hemodijalizi u pore -|enju sa kontrolnom grupom (p < 0,00001). Nisu na|ene statisti~ki zna~ajne razlike izme|u pacijenata i kontrolne grupe za vrednosti kalcijuma, fosfora i HbA1c. Nivoi CXC16 bili su u pozitivnoj korelaciji sa vrednostima CRP (r = 0,956, p < 0,00001) i iPTH (r = -0,403, p < 0,001). Pacijenti na hemodijalizi (dijabeti~ari ili hipertenzivni) imali su zna~ajno vi{e nivoe u pore|enju sa ne-dijabeti~arima ili sa pacijentima koji nisu bili hipertenzivni.
Background: CXC chemokine ligand 16 (CXCL16) is an inflammatory chemokine that mediates renal infiltration of macrophages and activated T cells.Aim: To investigate serum levels of CXCL16 in patients undergoing hemodialysis and their correlation with other inflammatory markers such as C-reactive protein (CRP) and intact parathyroid hormone (iPTH).Methods: The study included 40 hemodialysis patients (22 males) and 40 age and gender-matched controls (24 males). Fasting blood sugar (FBS), urea, creatinine, calcium and inorganic phosphorous were assayed in participants using routine methods, glycosylated hemoglobin (HbA1c) by quantitative chromatographic spectrophoto metry, iPTH by chemiluminescent microparticle immuno assay, CRP by nephelometry and CXCL16 by ELISA technique.Results: Serum CXCL16, CRP, PTH, FBS, urea, and creatinine levels were significantly higher in hemodialysis patients compared to controls (p<0.00001). No statistically significant differences were observed between patients and controls for calcium, phosphorous, and HbA1c. SerumCXCL16 levels correlated positively with CRP (r=0.956, p<0.00001) and iPTH (r=-0.403, p<0.001). Hemodialysis patients (diabetics or hypertensives) had significantly higher CXCL16 levels compared to non-diabetics or nonhypertensives. Conclusions: High levels of serum CXCL16, CRP and iPTH reflect the inflammatory status of hemodialysis patients and help avoid complications. Serum CXCL16 could be used as a biomarker together with CRP in these patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.